Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint inflammation and cartilage and bone tissue destruction. Although there exist some treatment strategies for RA, they are not completely safe and effective. Therefore, it is important to develop and test new drugs for RA that specifically target inflamed/swollen joints and simultaneously attenuate other possible damages to healthy tissues. Nanotechnology can be a good alternative to consider when envisioning precise medication for treating RA. Through the use of nanoparticles, it is possible to increase bioavailability and bioactivity of therapeutics and enable selective targeting to damaged joints. Herein, recent studies using nanoparticles for the treatment of RA, namely with liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been reviewed. These therapeutic strategies have shown great promise in improving the treatment over that by traditional drugs. The results of these studies confirm that feasibility of the use of nanoparticles is mainly due to their biocompatibility, low toxicity, controlled release, and selective drug delivery to inflamed tissues in animal RA models. Therefore, it is possible to claim that nanotechnology will, in the near future, play a crucial role in advanced treatments and patient-specific therapies for human diseases such as RA.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barnes, T.; Moots, R. Targeting nanomedicines in the treatment of rheumatoid arthritis: Focus on certolizumab pegol. Int. J. Nanomedicine 2007, 2, 3–7.
Howard, K. A.; Paludan, S. R.; Behlke, M. A.; Besenbacher, F.; Deleuran, B.; Kjems, J. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 2009, 17, 162–168.
Markides, H.; Kehoe, O.; Morris, R. H.; El Haj, A. J. Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells—A rheumatoid arthritis mouse model. Stem Cell Res. Ther. 2013, 4, 126.
Ishihara, T.; Kubota, T.; Choi, T.; Higaki, M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther. 2009, 329, 412–417.
McInnes, I. B.; Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7, 429–442.
Marrelli, A.; Cipriani, P.; Liakouli, V.; Carubbi, F.; Perricone, C.; Perricone, R.; Giacomelli, R. Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation? Autoimmun. Rev. 2011, 10, 595–598.
Pham, C. T. N. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2011, 3, 607–619.
Oda, K.; Minata, M. Drug free remission after steroiddependent disappearance of lymphoproliferative disorder in rheumatoid arthritis patient treated with TNF-alpha blockade: Case study. SpringerPlus 2015, 4, 41.
Stoll, J. G.; Yasothan, U. Rheumatoid arthritis market. Nat. Rev. Drug Discov. 2009, 8, 693–694.
Hwang, J.; Rodgers, K.; Oliver, J. C.; Schluep, T. α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomedicine 2008, 3, 359–371.
Rubinstein, I.; Weinberg, G. L. Nanomedicines for chronic non-infectious arthritis: The clinician’s perspective. Maturitas 2012, 73, 68–73.
Boulaiz, H.; Alvarez, P. J.; Ramirez, A.; Marchal, J. A.; Prados, J.; Rodríguez-Serrano, F.; Perán, M.; Melguizo, C.; Aranega, A. Nanomedicine: Application areas and development prospects. Int. J. Mol. Sci. 2011, 12, 3303–3321.
Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83, 761–769.
Mukherjee, B. Nanosize drug delivery system. Curr. Pharm. Biotechnol. 2013, 14, 1221.
Parveen, S.; Misra, R.; Sahoo, S. K. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8, 147–166.
Merisko-Liversidge, E. M.; Liversidge, G. G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36, 43–48.
Kahlenberg, J. M.; Fox, D. A. Advances in the medical treatment of rheumatoid arthritis. Hand Clin. 2011, 27, 11–20.
Abhilash, M. Potential applications of Nanoparticles. Int. J. Pharm. Bio Sci. 2010, 1, 1–12.
Mudshinge, S. R.; Deore, A. B.; Patil, S.; Bhalgat, C. M. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharmaceut. J. 2011, 19, 129–141.
Surendiran, A.; Sandhiya, S.; Pradhan, S. C.; Adithan, C. Novel applications of nanotechnology in medicine. Indian J. Med. Res. 2009, 130, 689–701.
Malam, Y.; Loizidou, M.; Seifalian, A. M. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30, 592–599.
Foong, W. C.; Green, K. L. Association of liposomeentrapped [3H] methotrexate with thioglycollate-elicited macrophages in-vitro. J. Pharm. Pharmacol. 1988, 40, 171–175.
Tarner, I. H.; Müller-Ladner, U. Drug delivery systems for the treatment of rheumatoid arthritis. Exp. Opin. Drug Deliv. 2008, 5, 1027–1037.
Kapoor, B.; Singh, S. K.; Gulati, M.; Gupta, R.; Vaidya, Y. Application of liposomes in treatment of rheumatoid arthritis: Quo vadis. Sci. World J. 2014, 2014, 978351.
Love, W. G.; Amos, N.; Kellaway, I. W.; Williams, B. D. Specific accumulation of technetium-99m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: Effect of liposome size. Ann. Rheum. Dis. 1989, 48, 143–148.
van Lent, P. L. E. M.; Holthuysen, A. E. M.; van Rooijen, N.; van De Putte, L. B. A.; van Den Berg, W. B. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann. Rheum. Dis. 1998, 57, 408–413.
Ulbrich, W.; Lamprecht, A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. Roy. Soc. Interface 2010, 7(Suppl 1), S55–S66.
van den Hoven, J. M.; van Tomme, S. R.; Metselaar, J. M.; Nuijen, B.; Beijnen, J. H.; Storm, G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol. Pharmaceutics 2011, 8, 1002–1015.
Williams, A. S.; Camilleri, J. P.; Williams, B. D. Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat. Rheumatology 1994, 33, 530–533.
Watson-Clark, R. A.; Banquerigo, M. L.; Shelly, K.; Hawthorne, M. F.; Brahn, E. Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: Boron delivery by liposomes in rat collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 1998, 95, 2531–2534.
Chowdhary, R. K.; Ratkay, L. G.; Canaan, A. J.; Waterfield, J. D.; Richter, A. M.; Levy, J. G. Uptake of Verteporfin® by articular tissues following systemic and intra-articular administration. Biopharm. Drug Dispos. 1998, 19, 395–400.
Highton, J.; Guévremont, D.; Thomson, J.; Carlisle, B.; Tucker, I. A trial of clodronate-liposomes as anti-macrophage treatment in a sheep model of arthritis. Clin. Exp. Rheumatol. 1999, 17, 43–48.
Corvo, M. L.; Boerman, O. C.; Oyen, W. J. G.; Jorge, J. C. S.; Cruz, M. E. M.; Crommelin, D. J. A.; Storm, G. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: In vivo fate and therapeutic activity in an inflammation model. Pharm. Res. 2000, 17, 600–606.
Srinath, P.; Chary, M. G.; Vyas, S. P.; Diwan, P. V. Long-circulating liposomes of indomethacin in arthritic rats—A biodisposition study. Pharm. Acta Helv. 2000, 74, 399–404.
Čeponis, A.; Waris, E.; Mönkkönen, J.; Laasonen, L.; Hyttinen, M.; Solovieva, S. A.; Hanemaaijer, R.; Bitsch, A.; Konttinen, Y. T. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum. 2001, 44, 1908–1916.
Trif, M.; Guillen, C.; Vaughan, D. M.; Telfer, J. M.; Brewer, J. M.; Roseanu, A.; Brock, J. H. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp. Biol. Med. 2001, 226, 559–564.
Trif, M.; Roseanu, A.; Brock, J. H.; Brewer, J. M. Designing lipid nanostructures for local delivery of biologically active macromolecules. J. Liposome Res. 2007, 17, 237–248.
Everts, M.; Koning, G. A.; Kok, R. J.; Ásgeirsdóttir, S. A.; Vestweber, D.; Meijer, D. K. F.; Storm, G.; Molema, G. In vitro cellular handling and in vivo targeting of E-selectindirected immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res. 2003, 20, 64–72.
Mitragotri, S.; Yoo, J.-W. Designing micro- and nanoparticles for treating rheumatoid arthritis. Arch. Pharm. Res. 2011, 34, 1887–1897.
Metselaar, J. M.; Wauben, M. H. M.; Wagenaar-Hilbers, J. P. A.; Boerman, O. C.; Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arth. Rheumatol. 2003, 48, 2059–2066.
Metselaar, J. M.; Van den Berg, W. B.; Holthuysen, A. E. M.; Wauben, M. H. M.; Storm, G.; Van Lent, P. L. E. M. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis. 2004, 63, 348–353.
Harigai, T.; Hagiwara, H.; Ogawa, Y.; Ishizuka, T.; Kaneda, S.; Kimura, J. Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: A novel approach to rheumatoid arthritis therapy. J. Pharm. Pharmacol. 2007, 59, 137–143.
Koning, G. A.; Schiffelers, R. M.; Wauben, M. H. M.; Kok, R. J.; Mastrobattista, E.; Molema, G.; ten Hagen, T. L. M.; Storm, G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arth. Rheumatol. 2006, 54, 1198–1208.
Hattori, Y.; Sakaguchi, M.; Maitani, Y. Folate-linked lipidbased nanoparticles deliver a NFκB decoy into activated murine macrophage-like RAW264.7 cells. Biol. Pharm. Bull. 2006, 29, 1516–1520.
Rauchhaus, U.; Kinne, R. W.; Pohlers, D.; Wiegand, S.; Wölfert, A.; Gajda, M.; Bräuer, R.; Panzner, S. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 2009, 68, 1933–1934.
Richards, P. J.; Williams, A. S.; Goodfellow, R. M.; Williams, B. D. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology 1999, 38, 818–825.
Richards, P. J.; Williams, B. D.; Williams, A. S. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology 2001, 40, 978–987.
Simões, S.; Delgado, T. C.; Lopes, R. M.; Jesus, S.; Ferreira, A. A.; Morais, J. A.; Cruz, M. E. M.; Corvo, M. L.; Martins, M. B. F. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes. J. Control. Release 2005, 103, 419–434.
Gaspar, M. M.; Boerman, O. C.; Laverman, P.; Corvo, M. L.; Storm, G.; Cruz, M. E. M. Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J. Control. Release 2007, 117, 186–195.
Khoury, M.; Louis-Plence, P.; Escriou, V.; Noel, D.; Largeau, C.; Cantos, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arth. Rheumatol. 2006, 54, 1867–1877.
Gerlag, D. M.; Borges, E.; Tak, P. P.; Ellerby, H. M.; Bredesen, D. E.; Pasqualini, R.; Ruoslahti, E.; Firestein, G. S. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arth. Res. Ther. 2001, 3, 357.
Kim, W. U.; Lee, W. K.; Ryoo, J. W.; Kim, S. H.; Kim, J.; Youn, J.; Min, S. Y.; Bae, E. Y.; Hwang, S. Y.; Park, S. H. et al. Suppression of collagen-induced arthritis by single administration of poly (lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of oral tolerance. Arth. Rheumatol. 2002, 46, 1109–1120.
Horisawa, E.; Kubota, K.; Tuboi, I.; Sato, K.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Size-dependency of DL-lactide/ glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm. Res. 2002, 19, 132–139.
Butoescu, N.; Jordan, O.; Doelker, E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: A review of the factors influencing their performance. Eur. J. Pharm. Biopharm. 2009, 73, 205–218.
Fiehn, C.; Müller-Ladner, U.; Gay, S.; Krienke, S.; Freudenberg-Konrad, S.; Funk, J.; Ho, A. D.; Sinn, H.; Wunder, A. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology 2004, 43, 1097–1105.
Ren, K.; Dusad, A.; Dong, R.; Quan, L. D. Albumin as a delivery carrier for rheumatoid arthritis. J. Nanomed. Nanotechol. 2013, 4, 176.
Higaki, M.; Ishihara, T.; Izumo, N.; Takatsu, M.; Mizushima, Y. Treatment of experimental arthritis with poly (D, L-lactic/ glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis. 2005, 64, 1132–1136.
Patel, J.; Jigar, B.; Shah, H.; Patel, D. Novel drug delivery technologies for the treatment of rheumatoid arthritis. Internet J. Med. Technol. 2008, 5, 1–11.
Liu, M. X.; Dong, J.; Yang, Y. J.; Yang, X. L.; Xu, H. B. Anti-inflammatory effects of triptolide loaded poly (D, L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. J. Ethnopharmacol. 2005, 97, 219–225.
Mansouri, S.; Cuie, Y.; Winnik, F.; Shi, Q.; Lavigne, P.; Benderdour, M.; Beaumont, E.; Fernandes, J. C. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 2006, 27, 2060–2065.
Wang, D.; Miller, S. C.; Liu, X.-M.; Anderson, B.; Wang, X. S.; Goldring, S. R. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arth. Res. Ther. 2007, 9, R2.
Rothenfluh, D. A.; Bermudez, H.; O’Neil, C. P.; Hubbell, J. A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat. Mater. 2008, 7, 248–254.
Ishihara, T.; Takahashi, M.; Higaki, M.; Mizushima, Y.; Mizushima, T. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int. J. Pharm. 2010, 385, 170–175.
Liu, X.-M.; Quan, L.-D.; Tian, J.; Laquer, F. C.; Ciborowski, P.; Wang, D. Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 2010, 11, 2621–2628.
Kim, Y.-J.; Chae, S. Y.; Jin, C.-H.; Sivasubramanian, M.; Son, S.; Choi, K. Y.; Jo, D.-G.; Kim, K.; Kwon, I. C.; Lee, K. C. et al. Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. Biomaterials 2010, 31, 9057–9064.
Schmitt, F.; Lagopoulos, L.; Käuper, P.; Rossi, N.; Busso, N.; Barge, J.; Wagnières, G.; Laue, C.; Wandrey, C.; Juillerat-Jeanneret, L. Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints. J. Control. Release 2010, 144, 242–250.
Shi, Q.; Wang, H. J.; Tran, C.; Qiu, X. P.; Winnik, F. M.; Zhang, X. L.; Dai, K. R.; Benderdour, M.; Fernandes, J. C. Hydrodynamic delivery of chitosan-folate-DNA nanoparticles in rats with adjuvant-induced arthritis. J. Biomed. Biotechnol. 2011, 2011, Article ID 148763.
Scheinman, R. I.; Trivedi, R.; Vermillion, S.; Kompella, U. B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine 2011, 6, 1669–1682.
Ryu, J. H.; Lee, A.; Chu, J. U.; Koo, H.; Ko, C. Y.; Kim, H. S.; Yoon, S. Y.; Kim, B. S.; Choi, K.; Kwon, I. C. et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arth. Rheumatol. 2011, 63, 3824–3832.
Park, K. S.; Kang, J. H.; Sa, K. H.; Koo, H. B.; Cho, H. J.; Nam, E. J.; Youn, I. C.; Kim, K. M.; Kim, I. S.; Kwon, I. C. et al. In vivo quantitative measurement of arthritis activity based on hydrophobically modified glycol chitosan in inflammatory arthritis: More active than passive accumulation. Mol. Imaging 2012, 11, 389–400.
Te Boekhorst, B. C. M.; Jensen, L. B.; Colombo, S.; Varkouhi, A. K.; Schiffelers, R. M.; Lammers, T.; Storm, G.; Nielsen, H. M.; Strijkers, G. J.; Foged, C. et al. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J. Control. Release 2012, 161, 772–780.
Rollett, A.; Reiter, T.; Nogueira, P.; Cardinale, M.; Loureiro, A.; Gomes, A.; Cavaco-Paulo, A.; Moreira, A.; Carmo, A. M.; Guebitz, G. M. Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. Int. J. Pharm. 2012, 427, 460–466.
Albuquerque, J.; Moura, C. C.; Sarmento, B.; Reis, S. Solid lipid nanoparticles: A potential multifunctional approach towards rheumatoid arthritis theranostics. Molecules 2015, 20, 11103–11118.
Kim, S.-H.; Kim, J.-H.; You, D. G.; Saravanakumar, G.; Yoon, H. Y.; Choi, K. Y.; Thambi, T.; Deepagan, V. G.; Jo, D.-G.; Park, J. H. Self-assembled dextran sulphate nanoparticles for targeting rheumatoid arthritis. Chem. Commun. 2013, 49, 10349–10351.
Heo, R.; Park, J.-S.; Jang, H. J.; Kim, S.-H.; Shin, J. M.; Suh, Y. D.; Jeong, J. H.; Jo, D.-G.; Park, J. H. Hyaluronan nanoparticles bearing γ-secretase inhibitor: In vivo therapeutic effects on rheumatoid arthritis. J. Control. Release 2014, 192, 295–300.
Lee, S. J.; Lee, A.; Hwang, S. R.; Park, J.-S.; Jang, J.; Huh, M. S.; Jo, D.-G.; Yoon, S.-Y.; Byun, Y.; Kim, S. H. et al. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol. Ther. 2014, 22, 397–408.
Bilthariya, U.; Jain, N.; Rajoriya, V.; Jain, A. K. Folateconjugated albumin nanoparticles for rheumatoid arthritistargeted delivery of etoricoxib. Drug Dev. Ind. Pharm. 2015, 41, 95–104.
Oliveira, J. M.; Kotobuki, N.; Marques, A. P.; Pirraco, R. P.; Benesch, J.; Hirose, M.; Costa, S. A.; Mano, J. F.; Ohgushi, H.; Reis, R. L. Surface engineered carboxymethylchitosan/ poly(amidoamine) dendrimer nanoparticles for intracellular targeting. Adv. Funct. Mater. 2008, 18, 1840–1853.
Yu, M. M.; Jie, X.; Xu, L.; Chen, C.; Shen, W. L.; Cao, Y. N.; Lian, G.; Qi, R. Recent advances in dendrimer research for cardiovascular diseases. Biomacromolecules 2015, 16, 2588–2598.
Wu, L.-P.; Ficker, M.; Christensen, J. B.; Trohopoulos, P. N.; Moghimi, S. M. Dendrimers in medicine: Therapeutic concepts and pharmaceutical challenges. Bioconjugate Chem. 2015, 26, 1198–1211.
Chandrasekar, D.; Sistla, R.; Ahmad, F. J.; Khar, R. K.; Diwan, P. V. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J. Biomed. Mater. Res. A 2007, 82, 92–103.
Thomas, T. P.; Goonewardena, S. N.; Majoros, I. J.; Kotlyar, A.; Cao, Z. Y.; Leroueil, P. R.; Baker, J. R. Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arth. Rheumatol. 2011, 63, 2671–2680.
Hayder, M.; Poupot, M.; Baron, M.; Nigon, D.; Turrin, C.-O.; Caminade, A.-M.; Majoral, J.-P.; Eisenberg, R. A.; Fournié, J.-J.; Cantagrel, A. et al. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci. Trans. Med. 2011, 3, 81ra35.
Bosch, X. Dendrimers to treat rheumatoid arthritis. ACS Nano 2011, 5, 6779–6785.
Edmundson, M. C.; Capeness, M.; Horsfall, L. Exploring the potential of metallic nanoparticles within synthetic biology. New Biotechnol. 2014, 31, 572–578.
Mody, V. V.; Siwale, R.; Singh, A.; Mody, H. R. Introduction to metallic nanoparticles. J. Pharm. Bioallied Sci. 2010, 2, 282–289.
Tsai, C. Y.; Shiau, A. L.; Chen, S. Y.; Chen, Y. H.; Cheng, P. C.; Chang, M. Y.; Chen, D. H.; Chou, C. H.; Wang, C. R.; Wu, C. L. Amelioration of collagen-induced arthritis in rats by nanogold. Arth. Rheumatol. 2007, 56, 544–554.
Chamberland, D. L.; Agarwal, A.; Kotov, N.; Fowlkes, J. B.; Carson, P. L.; Wang, X. D. Photoacoustic tomography of joints aided by an Etanercept-conjugated gold nanoparticle contrast agent—An ex vivo preliminary rat study. Nanotechnology 2008, 19, 095101.
Lee, H.; Lee, K.; Kim, I. K.; Park, T. G. Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes. Biomaterials 2008, 29, 4709–4718.
Huang, Y.-J.; Shiau, A.-L.; Chen, S.-Y.; Chen, Y.-L.; Wang, C.-R.; Tsai, C.-Y.; Chang, M.-Y.; Li, Y.-T.; Leu, C.-H.; Wu, C.-L. Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering. Eur. Cell. Mater. 2012, 23, 170–181.
Lee, S.-M.; Kim, H. J.; Ha, Y.-J.; Park, Y. N.; Lee, S.-K.; Park, Y.-B.; Yoo, K.-H. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano 2013, 7, 50–57.
Lee, H.; Lee, M.-Y.; Bhang, S. H.; Kim, B.-S.; Kim, Y. S.; Ju, J. H.; Kim, K. S.; Hahn, S. K. Hyaluronate–gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano 2014, 8, 4790–4798.
Schulze, K.; Koch, A.; Schöpf, B.; Petri, A.; Steitz, B.; Chastellain, M.; Hofmann, M.; Hofmann, H.; von Rechenberg, B. Intraarticular application of superparamagnetic nanoparticles and their uptake by synovial membrane—An experimental study in sheep. J. Magn. Magn. Mater. 2005, 293, 419–432.
Kim, J.; An, H. Y.; Rieter, W. J.; Esserman, D.; Taylor-Pashow, K. M. L.; Sartor, R. B.; Lin, W.; Tarrant, T. K. Multimodal optical and Gd-based nanoparticles for imaging in inflammatory arthritis. Clin. Exp. Rheumatol. 2009, 27, 580–586.
Prasad, S. R.; Elango, K.; Damayanthi, D.; Saranya, J. S. Formulation and evaluation of azathioprine loaded silver nanopartilces for the treatment of rheumatoid arthritis. Asian J. Biomed. Pharm. Sci. 2013, 3, 28–32.
Ye, J. S.; Wang, Q.; Zhou, X. F.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm. 2008, 352, 273–279.
Xue, M.; Jiang, Z.-Z.; Wu, T.; Li, J.; Zhang, L.; Zhao, Y.; Li, X.-J.; Zhang, L.-Y.; Yang, S.-Y. Anti-inflammatory effects and hepatotoxicity of Tripterygium-loaded solid lipid nanoparticles on adjuvant-induced arthritis in rats. Phytomedicine 2012, 19, 998–1006.
Nagai, N.; Ito, Y. Effect of solid nanoparticle of indomethacin on therapy for rheumatoid arthritis in adjuvant-induced arthritis rat. Biolog. Pharm. Bull. 2014, 37, 1109–1118.
Zhou, H.-F.; Chan, H. W.; Wickline, S. A.; Lanza, G. M.; Pham, C. T. N. αvβ3-Targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009, 23, 2978–2985.
Koo, O. M. Y.; Rubinstein, I.; Önyüksel, H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm. Res. 2011, 28, 776–787.
Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34, D668–D672.
Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A computer-based archival file for macromolecular structures. Arch. Biochem. Biophys. 1978, 185, 584–591.
Barrera, P.; Mulder, S.; Smetsers, A. I.; Storm, G.; Beijnen, J. H.; Metselaar, J. M.; van Riel, P. L. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. In Arthritis and Rheumatism; Wiley-Liss Div John Wiley & Sons Inc: USA, 2008; pp 3976–3977.
Acknowledgements
The authors thank the financial support under the ARTICULATE project (No. QREN-13/SI/2011-23189). This study was also funded by the Portuguese Foundation for Science and Technology (FCT) project OsteoCart (No. PTDC/CTM-BPC/115977/2009), as well as the European Union’s FP7 Programme under grant agreement no REGPOT-CT2012-316331-POLARIS. The FCT distinction attributed to J. M. O. under the Investigator FCT program (No. IF/00423/2012) is also greatly acknowledged. C. G. also wished to acknowledge FCT for supporting her research (No. SFRH/BPD/94277/2013).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Oliveira, I.M., Gonçalves, C., Reis, R.L. et al. Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends. Nano Res. 11, 4489–4506 (2018). https://doi.org/10.1007/s12274-018-2071-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12274-018-2071-3